Krystal Biotech Inc (KRYS)

A. Company Overview

Krystal Biotech Inc. is a fully integrated, commercial-stage biotechnology firm engaged in the discovery, development, and commercialization of genetic medicines. The company's core mission is directed towards addressing diseases that exhibit high unmet medical needs. The company achieved a significant milestone with the FDA approval of its first commercial product, VYJUVEK® (also known as B-VEC outside the U.S.), on May 19, 2023. This product is specifically designed to treat Dystrophic Epidermolysis Bullosa (DEB), becoming the first-ever FDA-approved therapy for this condition, which has historically had limited treatment options.

In utilizing a patented gene therapy technology platform based on engineered Herpes Simplex Virus type 1 (HSV-1), Krystal Biotech develops vectors that efficiently deliver therapeutic transgenes to targeted cells across various organ systems. This cell-specific mechanism facilitates the transcription and translation of the encoded effector to target and potentially remediate the underlying disease. The delivery methods for these therapies are designed to be non-invasive or minimally invasive, aiming for administration in healthcare settings and potentially directly at patients' homes by trained healthcare professionals. The overarching objective of Krystal Biotech is to devise user-friendly medicines that can significantly enhance the quality of life for individuals afflicted with rare and serious diseases.

Krystal Biotech boasts an in-house, FDA-inspected commercial-scale Current Good Manufacturing Practice (CGMP) facility, alongside an additional completed and qualified CGMP facility slated for future expansion. The company maintains exclusive rights to develop, manufacture, and commercialize both its FDA-approved product and its pipeline candidates worldwide. Although the primary focus is on creating gene therapies for severe and rare conditions, Krystal Biotech is also exploring applications of its platform for more prevalent or non-genetic diseases. To this end, the company launched Jeune Aesthetics, Inc., a wholly-owned subsidiary, in April 2019. This subsidiary is dedicated to undertaking preclinical and clinical assessments targeting aesthetic skin conditions.

B. Technology Platform

Krystal Biotech’s gene therapy platform is distinguished by several advantageous features of the HSV-1 virus, enhanced through targeted modifications. These advantages include:

• Repeat Administration: The company capitalizes on the natural capacity of HSV-1 to evade immune response, allowing for safer repeat administrations that can yield sustained therapeutic effects. This capability also facilitates treatment in patients with pre-existing antibodies to HSV-1.
• Non-Integrating Nature: Unlike certain other viral vectors that integrate into host cell DNA, the HSV-1 vector remains episomal. This non-integrating characteristic reduces the risk of disrupting essential host genes.
• Payload Capacity: The HSV-1 genome is expansive enough to accommodate larger transgenes, making it possible to encode multiple therapeutic genes. For instance, VYJUVEK incorporates two functional copies of the COL7A1 gene, which is sufficient to address the underlying cause of DEB.
• High Transduction Efficiency: With a natural affinity for epithelial cells, HSV-1 can achieve transduction efficiencies as high as 95% in cell-based studies, enhancing the delivery of therapeutic gene expression directly within patient tissues.
• Direct Delivery: The platform allows for minimally invasive local delivery of gene therapy, streamlining administration in clinical and home environments without necessitating hospitalization.
• Manufacturing Resilience: The HSV-1 vectors demonstrate stability under various conditions, facilitating production, storage, and distribution.

C. Product Portfolio

FDA Approved Product: VYJUVEK

VYJUVEK (beremagene geperpavec-svdt) is designed to treat DEB, a rare genetic skin disease caused by mutations in the COL7A1 gene. Affected individuals exhibit extremely fragile skin akin to the wings of a butterfly, with severe complications including chronic wounds and increased cancer risk. VYJUVEK addresses the genetic underpinning of DEB by delivering functional COL7A1 genes directly to the skin, fundamentally altering the disease's progression.

The product was commercially launched in the U.S. in the second quarter of 2023, and as of the end of that year, it has generated over $50 million in net revenue. The product is administered topically in a convenient manner, allowing for easy access both in clinic settings and at home.

Pipeline Programs

Krystal Biotech maintains a diverse pipeline targeting various conditions, including:

• Ophthalmology: Development of Ophthalmic B-VEC for ocular complications associated with DEB, with a patient population experiencing significant unmet needs in this area.
• Respiratory: KB407 is an inhaled gene therapy for cystic fibrosis, aiming to address the needs of patients with non-amenable genotypes to CRC inhibitors.
• Oncology: KB707 leverages immune-mediated mechanisms to target solid tumors, addressing the pressing need for effective cancer therapies.
• Dermatology: Investigational candidates KB105 and KB104 are aimed at addressing severe skin disorders, including ARCI and Netherton Syndrome, expanding the therapeutic landscape for dermatological conditions.
• Aesthetics: Jeune Aesthetics focuses on exploring applications in aesthetic dermatology, with KB301 designed to enhance skin quality through collagen gene expression.

D. Manufacturing Capabilities

The company's manufacturing infrastructure includes CGMP-compliant facilities optimized for developing and producing viral vectors. The first facility, ANCORIS, has been producing VYJUVEK, receiving favorable assessments during FDA audits. A second facility, ASTRA, was recently completed, significantly increasing production capacity while incorporating all stages of the manufacturing process in-house. The proprietary manufacturing technique ensures high consistency and reproducibility in vector production.

E. Competitive Landscape

Krystal Biotech operates in a highly competitive biotechnology and pharmaceutical environment, particularly in gene therapy. With unique technology and a focused product pipeline, Krystal competes against numerous developers in gene and cell therapies targeting similar conditions. Key competitors in DEB treatment include firms exploring autologous or grafting approaches, and companies providing palliative care treatments.

The ongoing developments in multiple therapeutic areas suggest significant competition; however, Krystal's differentiated approach through its gene therapy platform positions it favorably, particularly in offering corrective rather than merely symptomatic treatments.

F. Intellectual Property and Regulatory Landscape

The company relies on a robust framework of patent protections and regulatory designations, including Orphan Drug Designation and Fast Track Designation, to maintain exclusivity for its products and platforms. The regulatory support received from the FDA and EMA underlines both the potential and the urgency of addressing the medical needs through innovative therapeutic solutions.

Despite the promising prospects, challenges remain in the realms of patent litigation, compliance with complex regulations, and navigating the reimbursement landscape for innovative therapies. Continuous efforts are directed to safeguard proprietary rights while navigating the landscape effectively for commercializing the product pipeline successfully.